Gilead Sciences, Inc. $GILD is Verity & Verity LLC’s 10th Largest Position

Verity & Verity LLC decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 270,699 shares of the biopharmaceutical company’s stock after selling 13,079 shares during the quarter. Gilead Sciences makes up 2.4% of Verity & Verity LLC’s holdings, making the stock its 10th largest holding. Verity & Verity LLC’s holdings in Gilead Sciences were worth $30,048,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. GoalVest Advisory LLC grew its holdings in Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares in the last quarter. Harbor Asset Planning Inc. purchased a new stake in shares of Gilead Sciences in the 2nd quarter worth approximately $27,000. Putney Financial Group LLC boosted its stake in shares of Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares in the last quarter. Howard Hughes Medical Institute purchased a new position in Gilead Sciences during the second quarter valued at approximately $30,000. Finally, Kilter Group LLC bought a new position in Gilead Sciences in the second quarter worth approximately $33,000. 83.67% of the stock is currently owned by institutional investors.

Insider Activity at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction on Monday, December 29th. The shares were sold at an average price of $124.83, for a total transaction of $1,248,300.00. Following the sale, the chief executive officer directly owned 566,698 shares of the company’s stock, valued at $70,740,911.34. The trade was a 1.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kelly A. Kramer sold 2,805 shares of the company’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.10, for a total value of $356,515.50. Following the completion of the transaction, the director directly owned 1,339 shares in the company, valued at approximately $170,186.90. The trade was a 67.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 136,257 shares of company stock worth $16,855,192 in the last 90 days. 0.27% of the stock is owned by insiders.

Analysts Set New Price Targets

Several brokerages have issued reports on GILD. UBS Group raised Gilead Sciences to a “hold” rating in a research report on Thursday, December 4th. Needham & Company LLC upped their price objective on Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. BMO Capital Markets set a $135.00 price objective on Gilead Sciences in a research report on Tuesday, November 25th. Scotiabank began coverage on shares of Gilead Sciences in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 target price for the company. Finally, Wells Fargo & Company raised their price target on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $131.68.

Gilead Sciences Stock Down 0.9%

Shares of GILD stock opened at $121.60 on Friday. The stock’s fifty day moving average price is $123.05 and its 200 day moving average price is $117.05. Gilead Sciences, Inc. has a 1-year low of $88.57 and a 1-year high of $128.70. The company has a market cap of $150.87 billion, a price-to-earnings ratio of 18.85, a price-to-earnings-growth ratio of 0.65 and a beta of 0.32. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter last year, the company earned $2.02 earnings per share. The company’s quarterly revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Monday, December 15th were paid a $0.79 dividend. The ex-dividend date was Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.